Skip to content

US · ICUI · MEDICAL - INSTRUMENTS & SUPPLIES

ICU Medical, Inc. (ICUI) intrinsic value and stock valuation

$172.52as of 2026-11-21 · Mkt cap 4.61B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ICU Medical, Inc. DCF and intrinsic value

InvestorsCraft values ICUI with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from ICUI’s statements →

ICU Medical, Inc. Graham Number

Graham Number: $7.58d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies San Clemente, CA 92673 icumed.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.23B+11.9% 5y CAGRd
20112025
Net income
$730K-61.6% 5y CAGRd
20112025
Free cash flow
$91.8M-5.6% 5y CAGRd
20112025
Total equity
$2.12B+7.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.23B$2.38B$2.26B$2.28B$1.32B
Operating income$107M$43M$22.8M-$-42.9M$123.3M
Net income$730K-$-117.69M-$-29.66M-$-74.29M$103.1M
EPSd$29.3K-$-4.83M-$-1.23M-$-3.11M$4.74M
Operating cash flow$179.9M$204M$166.2M-$-62.13M$267.5M
Capital expenditure-$-88.04M-$-79.37M-$-93.67M-$-99.33M-$-81.17M
Free cash flow$91.8M$124.7M$72.5M-$-161.46M$186.4M
Total assets$4.05B$4.2B$4.38B$4.52B$1.88B
Total debt$1.39B$1.64B$1.7B$1.73B$45.1M
Net debt$1.08B$1.33B$1.45B$1.53B-$-507.78M
Total equity$2.12B$1.97B$2.12B$2.09B$1.62B
Cash and short-term investments$308M$308.6M$254.7M$213M$567.3M
Income statement
20252024202320222021
Revenue$2.23B$2.38B$2.26B$2.28B$1.32B
Cost of revenue$1.41B$1.56B$1.52B$1.58B$824.8M
Gross profit$819.7M$824.8M$739.9M$697.8M$491.5M
Research and development expenses$87.5M$88.6M$85.3M$93M$47.5M
Selling, general and administrative expenses$625.2M$638.8M$606.7M$608.4M$302.6M
Other expenses$0.00$54.4M$25M$39.3M$18.2M
Operating expenses$712.7M$781.8M$717.1M$740.7M$368.3M
Cost and expenses$2.12B$2.34B$2.24B$2.32B$1.19B
Interest income$10.3M$10.8M$7.51M$4.43M$2.84M
Interest expense$105.4M$106.5M$102.7M$70.8M$860K
Depreciation and amortization$218M$2.44M$228.8M$235.2M$99.3M
Ebitda$326.5M$43M$253.2M$191.6M$223.5M
Operating income$107M$43M$22.8M-$-42.9M$123.3M
Total other income/expenses, net-$-103.78M-$-108.98M-$-101.12M-$-71.51M-$-60K
Income before tax$3.17M-$-66.01M-$-78.3M-$-114.41M$123.2M
Income tax expense$2.44M$51.7M-$-48.64M-$-40.12M$20.1M
Net income$730K-$-117.69M-$-29.66M-$-74.29M$103.1M
Weighted average shares outstanding$24.6M$24.4M$24.1M$23.9M$21.2M
Weighted average diluted shares outstanding$24.9M$24.4M$24.1M$23.9M$21.8M
Balance sheet
20252024202320222021
Cash and short-term investments$308M$308.6M$254.7M$213M$567.3M
Net receivables$180.5M$202.7M$182.2M$246.9M$124.8M
Inventory$615.9M$584.7M$709.4M$696M$290.2M
Total current assets$1.18B$1.44B$1.22B$1.24B$1.03B
Property, plant and equipment, net$506.3M$499.3M$685.5M$713.6M$510.9M
Goodwill and intangible assets$2.13B$2.17B$2.34B$2.43B$231.8M
Long-term investments$131.6M$8.76M$3.12M$3.69M$7.86M
Total non-current assets$2.86B$2.76B$3.16B$3.28B$850.9M
Total assets$4.05B$4.2B$4.38B$4.52B$1.88B
Accounts payable$154.4M$148M$150M$215.9M$81.1M
Short-term debt$34.7M$66.7M$71.2M$47.9M$9.01M
Deferred revenue$33.8M$30.4M$31.6M$30.8M$12.7M
Total current liabilities$498.9M$556.2M$481.8M$494.6M$200.8M
Long-term debt$1.36B$1.57B$1.63B$1.69B$36M
Deferred revenue, non-current$0.00$9.04M$10.6M$16.2M$0.00
Total non-current liabilities$1.43B$1.68B$1.77B$1.93B$63.9M
Capital lease obligations$47.7M$58.8M$75.1M$80.9M$45.1M
Total liabilities$1.93B$2.24B$2.26B$2.43B$264.7M
Common stock$2.47M$2.45M$2.41M$2.4M$2.13M
Retained earnings$690.9M$690.2M$807.9M$837.5M$911.8M
Accumulated other comprehensive income (loss)-$-34.63M-$-139.4M-$-53.08M-$-80.98M-$-19.27M
Total equity$2.12B$1.97B$2.12B$2.09B$1.62B
Total investments$131.6M$8.76M$3.62M$7.92M$22.3M
Total debt$1.39B$1.64B$1.7B$1.73B$45.1M
Net debt$1.08B$1.33B$1.45B$1.53B-$-507.78M
Cash flow statement
20252024202320222021
Net income$730K-$-117.69M-$-29.66M-$-74.29M$103.1M
Depreciation and amortization$200.7M$240.9M$228.8M$235.2M$89.7M
Stock-based compensation$55.8M$46.9M$40.6M$36M$27.3M
Change in working capital-$-90.04M-$-2.57M-$-135.6M-$-303.73M$15M
Accounts receivable$8.88M-$-46.84M$48.6M-$-19.15M$13.8M
Inventory-$-26.25M$16.8M-$-6.08M-$-201.09M$20.8M
Accounts payable$7M$12.5M-$-68.3M$37.5M$2.35M
Net cash provided by operating activities$179.9M$204M$166.2M-$-62.13M$267.5M
Investments in property, plant and equipment-$-88.04M-$-79.37M-$-83.89M-$-90.31M-$-68.54M
Acquisitions, net$0.00$0.00$0.00-$-1.84B-$-14.45M
Net cash used for investing activities$122.2M-$-88.96M-$-87.95M-$-1.91B-$-90.69M
Common stock issued$6.11M$10.9M$4.02M$8.79M$9.37M
Common stock repurchased-$-8.77M-$-11.99M-$-9.35M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-311.52M-$-55.8M-$-35.98M$1.64B-$-16.87M
Net change in cash-$-600K$54.3M$45.4M-$-344.04M$156.7M
Cash at end of period$308M$308.6M$254.2M$208.8M$552.8M
Operating cash flow$179.9M$204M$166.2M-$-62.13M$267.5M
Capital expenditure-$-88.04M-$-79.37M-$-93.67M-$-99.33M-$-81.17M
Free cash flow$91.8M$124.7M$72.5M-$-161.46M$186.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ICU Medical, Inc.

        ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.

        CEO
        Vivek Jain
        Employees
        13K
        Beta
        0.76

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of ICU Medical, Inc. (ICUI)?

        ICU Medical, Inc. (ICUI) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ICUI undervalued?

        ICUI trades at a price of $172.52 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.